The goal of the YCC Proteomics Shared Resource (PSR) is to bring state-of-the-art technologies to bear on cancer research. These technologies include a wide range of mass spectrometric (MS) approaches to determine accurate molecular weights of proteins, peptides, small synthetic molecules (e.g., anti-cancer drugs), and other biomolecules. MS is also used for high throughput identification of proteins, typically following their enzymatic digestion. These proteins are often selected for identification based on their differential expression in normal versus cancer tissues or in response to chemotherapy. Protein profiling technologies used to interrogate the expression levels of hundreds of proteins include isotope-coded affinity tags (ICAT), differential (fluorescence) gel electrophoresis (DIGE), multiplexed tagging reagent (iTRAQ), and multidimensional protein identification technology (MudPIT). Unless MudPIT is combined with in vivo metabolic stable isotope labeling, its use is restricted to identifying the proteins that make up a given proteome. In each profiling experiment, a control is compared to a cancer or other experimental sample to identify proteins that are highly differentially expressed. Another approach for finding serum peptide biomarkers whose intensities can be used to diagnose cancer relies on methodologies and biostatistical algorithms implemented in the PSR to analyze MS spectra from large numbers of patients. Another PSR goal is to utilize advanced technologies, including the unique capabilities of its state-of-the-art 9.4T FT-ICR mass spectrometer, to identify protein post-translational modifications (PTM) such as phosphorylation, methylation, and others that often play important roles in modulating protein function and may be involved in tumorigenesis. Since the fraction of protein molecules bearing a given PTM is often low, methodologies are being implemented to enrich for proteins containing specific PTMs. Also of great importance to cancer research is the quantitative characterization of molecular interactions between biological molecules including proteins, nucleic acids, carbohydrates, lipids, and small molecules such as anti-cancer drugs. The Biophysics section of the PSR provides YCC investigators with several complementary technologies for: a) identifying the oligomeric state of interacting components, b) determining the stoichiometry of the interaction, and c) quantifying the forces responsible for macromolecular recognition and complex formation. Biophysical technologies available include: static and dynamic light scattering, steady-state and stopped-flow fluorescence and absorbance, isothermal calorimetry and surface plasmon resonance. Overall, 39 peer reviewed YCC investigators from 7 programs accounted for 19.8% of PSR services provided in CY2005.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-32
Application #
8132526
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
32
Fiscal Year
2010
Total Cost
$211,497
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Sarma, Elizabeth A; Kawachi, Ichiro; Poole, Elizabeth M et al. (2018) Social integration and survival after diagnosis of colorectal cancer. Cancer 124:833-840
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Zhang, Jinhua; Song, Kun; Wang, Jun et al. (2018) S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. Oncoimmunology 7:e1296996
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564
Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011

Showing the most recent 10 out of 675 publications